232 related articles for article (PubMed ID: 9516945)
1. The role of DNA mismatch repair in drug resistance.
Fink D; Aebi S; Howell SB
Clin Cancer Res; 1998 Jan; 4(1):1-6. PubMed ID: 9516945
[TBL] [Abstract][Full Text] [Related]
2. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin.
Lin X; Ramamurthi K; Mishima M; Kondo A; Christen RD; Howell SB
Cancer Res; 2001 Feb; 61(4):1508-16. PubMed ID: 11245458
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair.
Fink D; Zheng H; Nebel S; Norris PS; Aebi S; Lin TP; Nehmé A; Christen RD; Haas M; MacLeod CL; Howell SB
Cancer Res; 1997 May; 57(10):1841-5. PubMed ID: 9157971
[TBL] [Abstract][Full Text] [Related]
4. Analysis of microsatellite instability in acquired drug-resistance human tumor cell lines.
Picard SF; Franco N; Sergent C; Chauffert B; Lizard-Nacol S
Oncol Rep; 2002; 9(5):971-6. PubMed ID: 12168057
[TBL] [Abstract][Full Text] [Related]
5. Mutations in DNA mismatch repair genes: implications for DNA damage signaling and drug sensitivity (review).
Fedier A; Fink D
Int J Oncol; 2004 Apr; 24(4):1039-47. PubMed ID: 15010846
[TBL] [Abstract][Full Text] [Related]
6. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine.
Berry SE; Davis TW; Schupp JE; Hwang HS; de Wind N; Kinsella TJ
Cancer Res; 2000 Oct; 60(20):5773-80. PubMed ID: 11059773
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of geno- and cytotoxicity of methylnitrosourea on MMR-proficient and MMR-deficient human tumor cell lines].
Tronov VA; Kramarenko II; Smirnova TD; Terekhov SM
Tsitologiia; 2006; 48(1):19-27. PubMed ID: 16568831
[TBL] [Abstract][Full Text] [Related]
8. Role of mismatch repair in the induction of chromosomal aberrations and sister chromatid exchanges in cells treated with different chemotherapeutic agents.
Vernole P; Pepponi R; D'Atri S
Cancer Chemother Pharmacol; 2003 Sep; 52(3):185-92. PubMed ID: 12827294
[TBL] [Abstract][Full Text] [Related]
9. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
10. BRCA1 activates a G2-M cell cycle checkpoint following 6-thioguanine-induced DNA mismatch damage.
Yamane K; Schupp JE; Kinsella TJ
Cancer Res; 2007 Jul; 67(13):6286-92. PubMed ID: 17616687
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin: mechanism of action and antineoplastic activity.
Raymond E; Faivre S; Woynarowski JM; Chaney SG
Semin Oncol; 1998 Apr; 25(2 Suppl 5):4-12. PubMed ID: 9609103
[TBL] [Abstract][Full Text] [Related]
12. Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin.
Cenni B; Kim HK; Bubley GJ; Aebi S; Fink D; Teicher BA; Howell SB; Christen RD
Br J Cancer; 1999 May; 80(5-6):699-704. PubMed ID: 10360646
[TBL] [Abstract][Full Text] [Related]
13. DNA polymerase zeta accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair.
Lin X; Trang J; Okuda T; Howell SB
Clin Cancer Res; 2006 Jan; 12(2):563-8. PubMed ID: 16428501
[TBL] [Abstract][Full Text] [Related]
14. Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis.
Xu ZY; Loignon M; Han FY; Panasci L; Aloyz R
J Pharmacol Exp Ther; 2005 Aug; 314(2):495-505. PubMed ID: 15843498
[TBL] [Abstract][Full Text] [Related]
15. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
16. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.
Kelland LR; Sharp SY; O'Neill CF; Raynaud FI; Beale PJ; Judson IR
J Inorg Biochem; 1999 Oct; 77(1-2):111-5. PubMed ID: 10626362
[TBL] [Abstract][Full Text] [Related]
17. Erybraedin C and bitucarpin A, two structurally related pterocarpans purified from Bituminaria bituminosa, induced apoptosis in human colon adenocarcinoma cell lines MMR- and p53-proficient and -deficient in a dose-, time-, and structure-dependent fashion.
Maurich T; Iorio M; Chimenti D; Turchi G
Chem Biol Interact; 2006 Feb; 159(2):104-16. PubMed ID: 16271357
[TBL] [Abstract][Full Text] [Related]
18. The cell cycle phases of DNA damage and repair initiated by topoisomerase II-targeting chemotherapeutic drugs.
Potter AJ; Rabinovitch PS
Mutat Res; 2005 May; 572(1-2):27-44. PubMed ID: 15790488
[TBL] [Abstract][Full Text] [Related]
19. Involvement of the DNA mismatch repair system in antineoplastic drug resistance.
Lage H; Dietel M
J Cancer Res Clin Oncol; 1999; 125(3-4):156-65. PubMed ID: 10235469
[TBL] [Abstract][Full Text] [Related]
20. Cellular processing of platinum anticancer drugs.
Wang D; Lippard SJ
Nat Rev Drug Discov; 2005 Apr; 4(4):307-20. PubMed ID: 15789122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]